N95 masks, KN95 Masks, Disposable Mask Civil, 3-ply, Disposable Mask Surgical, 3-ply.Shipping
-Nitrile Gloves, Latex Gloves and all other types of gloves -Medical supplies -Medical equipment.
Fuel products like en590, jet fuel a1, many other fuel products .
Oil, Fuels, Metals, Food..
Used engine oil, re refined engine oil, base oil, all dress for gents,girls children. Leather products, coir products, lubricating oils, fertilizer, coal, activated carbon, readymade dresses, stationaries, xerox papers, corrugated boxes, cotton yarn.
Medical Equipment, Nitrile Gloves.
PPE and Gloves,Masks ,Sanitizer ,Gowns .
All ppe including hand sanitizer with fda certificate in liquid and gel, face masks, gowns, nitrile exam gloves in 4mil, covid 19 one step tests with instant results.
FFP2 NR (N95) Nanofiber Respirator Mask (SGS Compliance) Nitrile Examination Gloves N95 (NIOSH) Respirator KN95 Medical Mask LEV2 / 3-PLY Surgical Mask, LEV2 Full Body Surgical Gown COVID-19 Antibody (IgG/IgM) Testing Kits.
Medical screening tests using ai smartphone apps from real time network.
Wound closure device, sterile closure kits.
Microchanneling equipment and serums .
Home medical supplies & medical equipment .Shipping
Petroleum products such as ; jet a1, en590, d6........
Medical Equipment.
Diabetic test strips.
Medical equipment and supplies.Exporter
Due to contractual obligations to the federal government, Current suppliers have increased costs and limited production of all point of care tests without notice. We have great news! To shield our customers from excessive price increases as well as provide immediate availability, we have secured multiple FDA EUA rapid antigen test kit options. These tests have similar and/or better accuracy along with individual buffer bottles. We are currently able to provide three options: Clarity-Sienna, Indicaid and Celltrion DiaTrust kits. We work directly with the distributor and can supply by the pallet or case with pricing as low as $6.00 per kit.
CLIA Waived Use of this test with all authorized specimen types is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. 263a, that meet requirements to perform moderate or high complexity tests. This test is also authorized for use with fingerstick whole blood specimens only at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation. The CLIA Waived COVID-19 IgG/IgM Rapid Test Device is an in vitro immunoassay for the direct and qualitative detection of anti-SARS-CoV-2 IgM and anti-SARS-CoV-2 IgG in human whole blood, serum, or plasma. The test is for professional use only. Indication: Qualitative detection and differentiation of IgM and IgG antibodies to SARS-CoV-2 in human venous whole blood (sodium EDTA), serum, or plasma (sodium EDTA). Intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. Emergency use of this test is limited to authorized laboratories. About Test Device EUA Authorized CE Mark Test does NOT give positive or negative result for COVID-19 virus. This is an antibody test, it only indicates past or recent infection. Read Results in 15 Minutes 9 Month Expiration from Date of Manufacture Contents 20 Test Devices 20 Disposable Pipettes 20 Alcohol Prep Pads Sterile Safety Lancets Buffer Package Insert
The CareStart COVID-19 Antigen Test is a lateral flow immunochromatographic assay intended for the qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 in nasopharyngeal or anterior nasal swab specimens directly collected from individuals who are either suspected of COVID-19 by their healthcare provider within the first five days of symptom onset or from individuals without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over two or three days with at least 24 hours and no more than 48 hours between tests. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. 263a, that meet the requirements to perform moderate, high, or waived complexity tests. This test is authorized for use at the Point of Care (POC), i.e., inpatient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation. Lateral flow assay Detect SARS-CoV-2 nucleocapsid protein antigen Rapid results within 10-15 minutes Intended at POC setting (i.e., in patient care settings) by medical professionals operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation For use under the Emergency Use Authorization (EUA) only For in vitro diagnostic use only For prescription use only For use with direct anterior nasal and nasopharyngeal swab specimens Clinical Performance 93.75% PPAa and 99.32% NPAb when used with nasopharyngeal swab 87.18% PPAa and 100% NPAb when used with anterior nasal swab
